Quotient Wealth Partners LLC Lowers Holdings in Haleon plc (NYSE:HLN)

Quotient Wealth Partners LLC trimmed its position in shares of Haleon plc (NYSE:HLN) by 19.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 27,255 shares of the company’s stock after selling 6,541 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Haleon were worth $260,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Procyon Advisors LLC grew its holdings in shares of Haleon by 41.3% during the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock valued at $2,196,000 after buying an additional 67,329 shares during the last quarter. HighTower Advisors LLC boosted its stake in Haleon by 27.2% during the 3rd quarter. HighTower Advisors LLC now owns 350,795 shares of the company’s stock valued at $3,701,000 after purchasing an additional 74,970 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Haleon by 1,689.4% in the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock worth $2,803,000 after purchasing an additional 250,169 shares in the last quarter. Chartwell Investment Partners LLC raised its stake in shares of Haleon by 107.8% in the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock worth $5,030,000 after purchasing an additional 246,594 shares during the last quarter. Finally, Townsquare Capital LLC lifted its holdings in shares of Haleon by 29.8% during the third quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock valued at $5,032,000 after purchasing an additional 109,217 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Performance

Shares of HLN opened at $9.70 on Tuesday. The firm has a market capitalization of $43.89 billion, a P/E ratio of 28.51, a PEG ratio of 2.70 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The business has a fifty day moving average of $9.53 and a 200 day moving average of $9.79.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.